Introduction
The leading cause of vision loss in diabetic patients is diabetic macular edema (DME), which can occur at any stage of diabetic retinopathy (1, 2) . Until about a decade ago, macular laser photocoagulation was the mainstay of treatment for patients with DME, based on the historic Early Treatment Diabetic Retinopathy Study results demonstrating that this treatment achieved a 50% reduction of visual loss and increased rates of edema resolution and visual improvement (3) . However, following the identification of vascular endothelial growth factor (VEGF) and its pivotal role in the pathogenesis of DME, several prospective randomized controlled laser (24) (25) (26) (27) (28) (29) . However, these studies did not include patients who were also treated with anti-VEGF injections, which are currently the primary and most effective treatment for DME. The purpose of this study was to investigate the effect of micropulse laser in the treatment of DME at an early stage and its effect on the associated burden of anti-VEGF injections.
Methods

Patient selection
This retrospective chart review was approved by the institutional review board at the University of California, Davis. The study included patients treated for central (foveal-involving) DME with anti-VEGF injections and/or micropulse laser at the University of California Davis Eye Center and Health System between January 1, 2013, and June 30, 2015. The electronic and archived paper medical records of all identified subjects were retrospectively reviewed. All included patients were 18 years or older, and had at least 12 months of follow-up. Patients with other vision-limiting ocular conditions other than diabetic retinopathy (such as age-related macular degeneration, myopic degeneration, retinal vascular occlusions, amblyopia, advanced glaucoma, optic neuropathy, or corneal opacity) were excluded. Patients with a history of any ocular trauma or surgery except for uncomplicated cataract extraction with a posterior chamber intraocular lens implanted in the bag were excluded. Patients with documented macular ischemia on fluorescein angiography or a history of macular laser were also excluded, while patients who previously underwent panretinal photocoagulation were included. All included patients had no more than 3 prior intravitreal injections of ranibizumab (0.3 mg/0.05 mL; Lucentis, Genentech), which were administered monthly and the last injection more than 2 months prior to micropulse. Patients who were treated with intravitreal injections of other anti-VEGF agents or steroids were not included. None of the included patients underwent any ocular surgery or panretinal photocoagulation during the follow-up period.
After the group of patients who received micropulse laser for the treatment of DME was completed, a control group was identified from the patients who were treated for DME with ranibizumab injections but did not receive micropulse laser, using the same inclusion criteria in a 1:1 ratio. This group was controlled for age, sex, diabetic retinopathy stage, and length of follow-up status vs the micropulse group. Baseline was defined as the time of micropulse in the micropulse group and the time of first intravitreal injection of ranibizumab in the control group.
Data collection
The clinical data were retrieved from outpatient clinic charts. Recorded parameters included demographic information, general medical history, history of any previous ocular conditions, previous treatments for DME, details of the micropulse laser treatment, visual acuity (VA) at baseline and after 1, 3, 6, and 12 months, as well as at the final follow-up visit, additional treatments for DME throughout the follow-up, and the occurrence of any complications. Optical coherence tomography scans at each of the above time points were also evaluated for the presence of intraretinal fluid associated with DME, and central macular thickness (CMT) values were recorded. The OCT scans were acquired using a spectral-domain instrument (Cirrus, Carl Zeiss Meditec).
Outcome measures
The primary outcome was defined as the number of ranibizumab injections administered during the follow-up period. Secondary outcome measures included change in VA and CMT.
Micropulse laser technique
Topical anesthesia with proparacaine 0.5% drops was administered prior to the procedure. An Ocular Mainster lens (Ocular Instruments) was placed on the eye with a coupling gel for lubrication. Micropulse laser (yellow) was administered using the Iridex IQ 577 (Iridex Corporation) instrument, with the following settings: spot size of 200 μm, power of 400 mW, duration 200 ms, at 5% micropulse rate. Between 150 and 250 spots were used to cover the macula, in a high-density fashion with no overlap (26) . The first spot was placed away from the fovea to make sure no visible burn was achieved.
Statistical analysis
For statistical analysis, all VA values were converted to the logMAR scale. Unpaired 2-tailed Student t test was used to compare means of continuous parameters and a chi-square test was used to analyze proportions of categorical parameters. Paired 2-tailed Student t test was used to compare VA and CMT at different time points at the same group. A p value of less than 0.05 was used to declare a statistically significant difference between groups. Data were analyzed using SPSS for Windows, version 18.0 (SPSS Inc.).
Results
There were 19 eyes of 19 patients who were treated with micropulse laser for DME and fulfilled all of the inclusion criteria of this study. These patients included 7 (36.8%) women and 12 (63.2%) men, with a mean age of 65.3 ± 9.8 years (range 45-79 years). The control group included 19 eyes of 19 patients, and consisted of 6 (31.6%) women and 13 (68.4%) men with a mean age of 63.3 ± 8.9 years (range 47-81 years). There were 9 eyes that had previously been treated with panretinal laser photocoagulation: 5 in the micropulse group and 4 in the control group. In all of these cases, the laser treatment was completed more than 6 months before the beginning of DME treatment. The mean follow-up duration was 19.1 ± 8.9 months for the micropulse group and 23.2 ± 9.0 months for the control group. Table I summarizes the baseline parameters of both groups and their comparisons.
Visual acuity
In eyes treated with micropulse, baseline VA was 0.29 ± 0.12 logMAR (equivalent to 20/39), which had improved to 0.24 ± 0.17 logMAR (equivalent to 20/35; p = 0.06) at 12 months. Final VA was 0.25 ± 0.17 logMAR (equivalent to 20/35; p = 0.13) at the final follow-up. In control eyes, baseline VA was 0.41 ± 0.13 logMAR (equivalent to 20/51), which had improved to 0.39 ± 0.15 logMAR (equivalent to 20/49; p = 0.27) at 12 months and 0.36 ± 0.18 logMAR (equivalent to 20/45; p = 0.14) at the final follow-up. The changes in VA along the follow-up for both groups are presented in Figure 1 .
The mean baseline VA was significantly better in the micropulse group than the controls (p = 0.005). This difference was maintained throughout the study, and the VA at 12 months and at the end of the follow-up remained significantly better in the micropulse group (p = 0.005 and p = 0.03, respectively). Therefore, change in VA was also compared between the groups. The change in VA at 12 months was -0.06 ± 0.13 logMAR for the micropulse group and -0.06 ± 0.15 logMAR for the control group (p = 0.90), corresponding to an improvement of about half a line of vision. At the final follow-up, change in VA was -0.05 ± 0.14 logMAR for the micropulse group and -0.05 ± 0.15 logMAR for the control group (p = 0.93).
Central macular thickness
In eyes treated with micropulse, baseline CMT was 316.8 ± 91.5 µm, and had significantly declined to 282.6 ± 59.1 µm at 12 months (p = 0.05) and 280.2 ± 64.5 µm at the final follow-up (p = 0.04). In control eyes, baseline CMT was 408.4 ± 104.2 µm, and was significantly reduced to 335.9 ± 69.8 µm at 12 months (p = 0.02) and 314.7 ± 77.5 µm at the final followup (p = 0.006). The changes in CMT along the follow-up for both groups are presented in Figure 2 .
Mean baseline CMT was significantly lower in micropulsetreated eyes compared to control eyes (p = 0.005). The CMT at 12 months remained significantly lower in the micropulse group (p = 0.01), but not at the final follow-up (p = 0.14). Change in VA was also compared between the groups. The change in CMT was greater in the control group than in the micropulse, There was no statistically significant difference between the 2 groups. Of note is that the baseline visual acuity (VA) was better in the micropulse group, bordering on statistical significance. CMT = central macular thickness; NPDR = nonproliferative diabetic retinopathy; VEGF = vascular endothelial growth factor.
Fig. 1 -Mean ± SE of visual acuity (VA) values of patients treated with
micropulse and controls along the follow-up period. The VA was significantly better in the micropulse group at all points; however, the change in VA was comparable in both groups.
bordering on statistical significance at both 12 months and the final follow-up (p = 0.07 and 0.06, respectively).
Need for additional anti-VEGF injections
The micropulse group included 7 (36.8%) eyes that had received up to 3 ranibizumab injections prior to the micropulse laser. In the control group, the time of the first injection was defined as the first injection, so there could be no history of prior injections in those eyes. This led to a small but significant difference in the number of previously administered ranibizumab injections in both groups (p = 0.01). By 12 months, eyes in the micropulse group had received an additional 1.7 ± 2.3 injections, significantly less compared to 5.6 ± 2.1 in the control group (p<0.001). By the final follow-up, eyes in the micropulse group had received an additional 2.6 ± 3.3 injections, compared to 9.3 ± 5.1 in the control group (p<0.001). It should be noted that the injections administered prior to the study in the control group were not included in this analysis, in order to allow a comparison of the effects of the micropulse laser and prevent them from biasing the results towards a higher number of injections in the control group. The additional ranibizumab injections along the follow-up for both groups are presented in Figure 3 .
In order to compensate for this potential bias, the total number of injections the patients in both groups had received was also analyzed. This remained the same for the control group, but included the injections administered prior to micropulse therapy in the micropulse group. In this subanalysis, the total number of injections administered to eyes in the micropulse group was 2.3 ± 2.5 by 12 months and 3.2 ± 3.4 by the final follow-up. This remained significantly less than the number of injections administered to eyes in the control group at the same time points (p<0.001 for both).
Complications
No complications related to micropulse laser or intravitreal injections were encountered in this series. None of the patients underwent any ocular surgery during the follow-up period.
Discussion
Subthreshold micropulse laser for the treatment of DME is an appealing idea, as it may combine the well-established efficacy of macular laser with a significantly improved safety profile, and it may also have some advantages over intravitreal injections, as it is painless and longer-lasting. Previous studies have demonstrated that micropulse laser is effective in improving VA and decreasing macular thickness with high rates of DME resolution (24) (25) (26) (27) (28) (29) . It has been shown that the effects of micropulse laser are not immediate, and that it takes about a year to for them to be fully evident (26, 28, 29) . It has also been shown that the effect of micropulse laser is more significant in patients whose initial CMT is under 400 µm (25) , and that treating the macula in a high-density pattern results in greater visual and anatomic improvements (26). In this study, we evaluated the contribution of micropulse laser in the treatment of DME at its early stages, comparing patients who have received no more than 3 ranibizumab injections prior to micropulse laser with patients whose treatment was first initiated with ranibizumab injections. Our results are compatible with the previously published literature, and further support the use of micropulse laser in the treatment of DME, as better VA was maintained in the micropulse group throughout the follow-up.
There was a significant difference in baseline VA and CMT between groups, as patients who were treated with micropulse laser had better VA and lower CMT values than the controls. These differences are the result of the way patients were selected for micropulse laser treatment at our institution. Patients who presented with lower VA and/or retinal thickening with CMT over 400 µm were generally treated with ranibizumab injections, as that is currently the first-line treatment for DME (7, (11) (12) (13) . Because of the difference in baseline VA and CMT, we have included an analysis of the change in these parameters in both groups. We have found that VA and CMT have improved in both groups. The change in VA was the same in both groups, while the reduction in CMT was greater in the control group, which is expected given the higher baseline CMT values in this group.
This study is also the first to demonstrate a significant reduction in the number of additional intravitreal anti-VEGF injections required for the treatment of DME in patients who were treated with subthreshold micropulse laser. Our results showed that patients in the micropulse group required significantly fewer ranibizumab injections by 12 months and the effect was still maintained by the final follow-up visit. This finding is important in light of the fact that a similar degree of improvement in VA was achieved in both groups during their follow-up. All previous studies have included patients with DME who were not treated with anti-VEGF injections, and one study reported that in patients with baseline CMT of over 400 µm, micropulse was less effective and they required rescue anti-VEGF therapy (25) . This is the first report of this advantageous effect of including micropulse laser in the early treatment of patients with DME.
Limitations of this study include its medium size and retrospective nature. However, its comparative design and strict inclusion criteria achieved a homogenous patient population and constitute strengths. Other limitations include the lack of predefined criteria for micropulse laser, which was performed at the discretion of the treating clinicians, and absence of HbA1C levels of the patients at baseline. The differences in VA and CMT at baseline are also a limitation of this study; however, they are the result of the way patients were selected for micropulse laser and reflect the clinical reality. Patients who were offered micropulse lase tend to have CMT of under 400 µm, which may also explain their better VA, while patients with poorer VA at presentation or DME with retinal thickening beyond this threshold value tend to be treated with intravitreal injections. Despite these differences, the groups are clinically close enough to allow for a meaningful comparison, and the validity of their comparison is further supported by the marked difference in number of injections.
In conclusion, this study indicates that micropulse laser may have an important role in the treatment of DME, even in an era dominated by anti-VEGF therapy. It appears that in the early stages, before significant vision loss occurs, micropulse laser is an effective means of maintaining and improving VA, with an excellent safety profile. When used before or soon after anti-VEGF therapy is initiated, micropulse laser may improve VA and significantly decrease the number of additional injections required. As the effects of micropulse laser are slow to develop, it may be an effective addition to the therapeutic armamentarium that can be used relatively infrequently. We recommend considering micropulse laser therapy in patients with DME, especially if they still have relatively good VA and CMT of up to 400 µm, before or as an adjunct to anti-VEGF injections.
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